Format

Send to

Choose Destination
J Virol Methods. 1997 Nov;68(2):199-205.

A method for the detection and confirmation of antibodies to hepatitis C virus in dried blood spots.

Author information

1
Department of Virology, Camelia Botnar Laboratories, Hospital for Children, London, UK.

Abstract

This study describes the development and evaluation of a cost effective test rationale for the detection of anti-HCV in dried blood spots. Samples were screened using an 'in house' IgG ELISA that incorporated the recombinant proteins c22-3, c200 and NS5. Confirmation of specific antibody to HCV was by a modification of the immunoblot RIBA 3.0. An extensive panel of well evaluated anti-HCV positive and negative samples from the UK and South Africa were used to assess the sensitivity and specificity of the two tests. One third of the anti-HCV positive samples had been typed. All anti-HCV positive samples were detected by the 'in house' screening EIA. Test/negative optical density ratios showed that more than 95% of reactive samples produced values greater than 5.0. Antibodies to HCV could be detected in a wide range of samples derived from asymptomatic and symptomatic patients and of different genotypes, with similar sensitivity. The presence of anti-HCV could be confirmed by RIBA 3.0 in samples with low reactivity but not in anti-HCV negative samples. Furthermore the immunoblot assay successfully increased specificity by screening out false reactive EIA samples that might occur in an epidemiological survey of a multi-ethnic population.

PIP:

While hepatitis C virus (HCV) is a major etiological agent of post-transfusion and community acquired non-A, non-B hepatitis, little is known about the epidemiology of HCV in the UK. A cost-effective method using dried blood spots to determine anti-HCV IgG in subjects which could be used in large-scale epidemiological studies is described. Samples were screened using an in-house IgG ELISA incorporating the recombinant proteins c22-3, c200, and NS5, while specific antibody to HCV was confirmed using a modified immunoblot RIBA 3.0. A panel of well evaluated anti-HCV positive and negative samples from the UK and South Africa were used to assess the sensitivity and specificity of the 2 tests. All anti-HCV positive samples were detected by the in-house screening EIA. Test/negative optical density ratios showed that more than 95% of reactive samples produced values greater than 5.0. Antibodies to HCV could be detected in a wide range of samples derived from asymptomatic and symptomatic patients and of different genotypes, with similar sensitivity. The presence of anti-HCV could be confirmed by RIBA 3.0 in samples with low reactivity, but not in anti-HCV negative samples. The immunoblot assay increased specificity by screening out false reactive EIA samples.

PMID:
9389410
DOI:
10.1016/s0166-0934(97)00127-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center